Apollomics

Apollomics EBITDA per Share

The EBITDA per Share of Apollomics (APLM) as of Oct 16, 2026 is -4.41 USD. In the previous year, EBITDA per Share was -38.22 USD — a change of -88.45% (higher).

EBITDA per Share

-4.41USD

YoY

-88.45%

Last updated:

EBITDA per Share of Apollomics is 2025 -4.41 USD. EBITDA per Share of Apollomics was 2024 -38.22 USD. It decreases by -88.45% higher compared to the previous year.

The Apollomics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-7.73 USD
Jan 1, 2020
-11.28 USD
Jan 1, 2021
-378.68 USD
Jan 1, 2022
-51.94 USD
Jan 1, 2023
-59.36 USD
Jan 1, 2024
-38.22 USD
Jan 1, 2025
-4.41 USD
The Apollomics EBITDA per Share history
YEAREBITDA per ShareYoY
-4.41USD-88.45%
-38.22USD-35.62%
-59.36USD+14.30%
-51.94USD-86.28%
-378.68USD+3,257.51%
-11.28USD+45.93%
-7.73USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apollomics Stock analysis

What does Apollomics do? Apollomics Inc is a clinical-stage biotechnology company based in Foster City, California, operating within the Health Care sector. The company went public via an IPO on November 26, 2021, and is listed under the ticker APLM with ISIN KYG0411D1236. Apollomics focuses on the discovery and development of oncology therapies designed to address unmet medical needs. The company's pipeline includes approximately nine drug candidates, six of which are in clinical development. Its lead program involves vebreltinib (APL-101), a c-Met inhibitor being evaluated in a Phase II multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. Another key candidate is uproleselan (APL-106), an E-Selectin antagonist under development as an adjunct to standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Apollomics aims to create therapies that can be combined with existing treatments to enhance immune system engagement and target specific molecular pathways in cancer. The company's website is www.apollomicsinc.com. Apollomics is engaged in advancing innovative oncology treatments through clinical research and development. Apollomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apollomics stock

EBITDA per Share of Apollomics is -4.41 USD in 2025.

EBITDA per Share of Apollomics changed from -38.22 USD to -4.41 USD, representing a -88.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Apollomics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Apollomics

All Key Metrics — Apollomics